Project Grant R01AI192458
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,017,032 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Scripps Research Institute. The grant supports research to develop a single-shot sequential immunization regimen for HIV using atomic layer deposition (ALD) technology. The project aims to create a vaccine capable of eliciting broadly neutralizing antibodies (bNAbs) to provide effective protection...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $108,486 to the Scripps Research Institute to develop soluble and membrane-bound immunogens that can shepherd the maturation of broadly neutralizing antibodies (bnAbs) targeting the highly conserved membrane proximal external region (MPER) of the HIV-1 envelope protein. The goal is to advance the quest for a...
- This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,275,484 Cooperative Agreement to Weill Medical College of Cornell University on August 12, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of this project is to identify an optimal prime-boost immunization strategy to guide antibody maturation towards broad neutralization of HIV in early life. The project aims to: 1) Compare sequential versus simultaneous...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $791,661 to Duke University to develop a vaccine strategy for HIV-1. The key objectives are to optimize a vaccine delivery platform using integrase-defective lentiviral vectors (IDLVs) to persistently express HIV-1 envelope trimers and Gag antigen. The goal is to elicit durable neutralizing antibody and T-cell...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop a multivalent mRNA HIV vaccine that can elicit broadly neutralizing antibodies targeting the conserved envelope (Env) region of recently circulating subtype C HIV strains. The central hypothesis is that priming with a single Env immunogen followed by boosting with a multivalent Env immunogen set...
- This federal Project Grant award of $190,944, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to investigate the dynamics and formation of B cell immune memory in human vaccination. The research aims to systematically analyze human B cell, plasma cell, and antibody responses after HIV vaccination, and to dissect the mechanisms by which novel vaccine adjuvants like 3M-052-AF...
- The University of Pennsylvania received a $891,410 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on therapeutic vaccination strategies to boost autologous neutralizing antibodies for ART-free HIV control. The award is focused on testing whether individualized mRNA-LNP delivered Env immunogens can enhance baseline autologous neutralizing antibody responses...